DETAILED ACTION
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claims 94-116 are pending.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
Claims 97, 105 and 112 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claims 94, 102 and 110 recite that the subject has elevated PSA. However, claims 97, 105, 112 recite that PSA is an additional marker of prostate cancer. It is not clear how PSA can be an additional marker of prostate cancer when it has already been determined that PSA levels are elevated in the subject.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 94-116 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-23 of U.S. Patent No. 10,539,566. Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of U.S. Patent No. 10,539,566 are drawn to a method of treating prostate cancer in a subject suspected of having prostate
cancer, comprising: (i) obtaining a serum sample or a plasma sample from the
subject, wherein the subject has elevated PSA and is symptomatic of prostate cancer,
(ii) submitting the sample from the subject to obtain diagnostic information as to the
protein level of filamin A, (iii) administering a therapeutically effective amount of an
anti‐cancer therapy to the subject if the protein level of filamin A in the sample is
increased relative to the protein level of filamin A in a normal control sample,
wherein the anti‐cancer therapy is selected from the group consisting of (a) radiation
therapy, (b) chemotherapy, (c) surgery for resecting tumor tissues, (d) hormone
therapy, (e) antibody therapy, (f) immunotherapy, (g) cytokine therapy, (h) growth
factor therapy, and (i) any combination of (a)‐(h). Thus, the present claims are obvious over the allowed claims of U.S. Patent No. 10,539,566.
Alper et al (US 2010/0330593, 30 December 2010, IDS) teaches methods for diagnosing prostate cancer by measuring levels of filamin A in serum using ELISA and mass spectrometry (paragraphs 6-9, 19, 61, 78, 114). Alper further disclosed methods of treatment and identify resection and radiotherapy (paragraphs 1, 9, 40). Bedello et al (Clin Cancer Res, 15:788-796, 2009, IDS) disclose measuring filamin A on patient’s sample by immunohistochemistry (Figures 1 and 2). Neither Alper nor Bedello teach or suggest an association between filamin A and prostate cancer specifically, wherein an increased protein level of filamin A indicates that treatment for prostate cancer is necessary. Furthermore, Nakamura et al (US 2005/0259483, published November 24, 2005, IDS) discloses that filamin A is down-regulated in prostate cancer (Table 4, page 28).
Summary
No claims allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mark Halvorson whose telephone number is (571) 272-6539. The examiner can normally be reached on Monday through Friday from 9:00 am to 6:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gregory Emch, can be reached at (571) 272-8149. The fax phone number for this Art Unit is (571) 273-8300.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/MARK HALVORSON/ Primary Examiner, Art Unit 1646